Results 211 to 220 of about 144,436 (251)

Leptin Therapy Improves Metabolic Dysfunction in Immune Checkpoint Inhibitor-induced Lipodystrophy. [PDF]

JCEM Case Rep
Vahidi Rad M, Saad-Omer S, Suresh Kumar Bindu BN, Simha V.   +3 more
europepmc   +1 more source

Overcoming resistance to immune checkpoint inhibitor therapy in acute myeloid leukemia. [PDF]

Front Oncol
Agrawal V, Salhotra A.
europepmc   +1 more source

Immune Checkpoint Inhibitor-Induced Sarcoidosis-Like Reaction Mimicking Pulmonary Metastasis: A Case Report. [PDF]

Cureus
Sawada M, Kurose Y, Ochi Y, Kanno K, Andou M.   +4 more
europepmc   +1 more source

Severe Immune-Related Neurological Adverse Events Associated With Immune Checkpoint Inhibitor Treatment: A Retrospective Single-Center Study. [PDF]

Eur J Neurol
Grisold A, Starzer AM, Silvaieh S, Krenn M, Aretin MB, Schmidinger M, Ressler JM, Polterauer S, Berger T, Preusser M, Berghoff AS.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Immune Checkpoint Inhibitors in the Aged

Current Oncology Reports, 2021
Large phase III trials have established the benefit of checkpoint blockade across multiple tumor types, but patient representation is limited in some subgroups including the aged population. There are several changes in the immune system that occur with age (termed immunosenescence) that could potentially limit efficacy in aged populations.Despite the ...
James Isaacs, Scott Antonia, Jeffrey Clarke   +2 more
openaire   +2 more sources

Immune checkpoint inhibitors and vasculitis

Current Opinion in Rheumatology, 2020
Purpose of review Clinical use of immune checkpoint inhibitor (ICI) therapy has revolutionized the therapeutic landscape of cancer. By activating the immune system using monoclonal anti-CTLA-4 and PD(L)-1 antibodies, remission can be induced in previously terminal cancers. However, these breakthroughs come at a price.
Patrick, Boland, Jacqueline, Heath, Sabina, Sandigursky   +2 more
openaire   +2 more sources

Immune checkpoint inhibitors in GBM

Journal of Neuro-Oncology, 2021
The purpose of this review is to summarize recent updates regarding immune checkpoint inhibitor therapy in GBM patients including updates in brain immunology, clinical trials, mechanisms of resistance, and biomarkers of response.PubMed was searched to identify recent relevant articles on immune checkpoint inhibitor therapy as it pertains to GBM ...
openaire   +2 more sources

Immune Checkpoint Inhibitor Toxicity

Current Oncology Reports, 2018
Immune checkpoint inhibitors have revolutionised the treatment of multiple malignancies and have a growing list of indications. As our familiarity with these agents grows, so does our understanding of their unique spectrum of toxicities. Here, we will review the literature regarding the toxicities of checkpoint inhibitors and address challenges ...
David J, Palmieri, Matteo S, Carlino
openaire   +2 more sources

Cardiotoxicity of Immune Checkpoint Inhibitors

Current Treatment Options in Cardiovascular Medicine, 2019
Immunotherapies, particularly immune checkpoint inhibitors (ICI), are revolutionary cancer therapies being increasingly applied to a broader range of cancers. Our understanding of the mechanism, epidemiology, diagnosis, and treatment of cardiotoxicity related to immunotherapies remains limited.
Lili, Zhang, Maeve, Jones-O'Connor, Magid, Awadalla, Daniel A, Zlotoff, Paaladinesh, Thavendiranathan, John D, Groarke, Alexandra-Chloe, Villani, Alexander R, Lyon, Tomas G, Neilan   +8 more
openaire   +2 more sources